secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001847903-23-000095
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials
--------------------------------------------------------------------------------

- Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.
- Net loss attributable to shareholders $50.7M vs $54.5M YoY; R&D $32.8M (down 11%), G&A $16.1M (up 12%).
- SerpinPC registration program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected H2 2023.
- LB101 (PD-L1xCD47 LockBody) Phase 1/2a first-in-human trial dosing subjects for solid tumors.
- ORX750 (OX2R agonist for narcolepsy) in IND-enabling activities; preclinical data planned at 2023 scientific meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/0001847903-23-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/cnta-20230512.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer